Search research articles
Contact Us
Filters
Showing results (191-200 of 367) with videos related to
Page
of 37
Sort By:
Investigative Ophthalmology & Visual Science
|
May 1, 1987
Bullous pemphigoid autoantibodies are markers of corneal epithelial hemidesmosomes
G J Anhalt, H D Jampel, H P Patel, et al.
Ophthalmology
|
September 8, 2007
Periocular triamcinolone and photodynamic therapy for subfoveal choroidal neovascularization in age-related macular degeneration
, Marta M Gilson, Neil M Bressler, et al.
American Journal of Ophthalmology
|
October 29, 2021
Reply to Comment on: Classification Criteria for Behçet Disease Uveitis
Annabelle A Okada, Alan G Palestine, Michal Kramer, et al.
Ophthalmology
|
July 13, 2014
Author reply: To PMID 24359625
Russell W Read, Grace Levy-Clarke, Douglas A Jabs, et al.
Ophthalmology
|
December 24, 2013
Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders
Grace Levy-Clarke, Douglas A Jabs, Russell W Read, et al.
Arthritis and Rheumatism
|
July 1, 1989
Characterization of the class I HLA 9.2-kb PVU II restriction fragment length polymorphism. Linkage to HLA-A and lack of disease association
J M Ahearn, J J Calomiris, F M Wigley, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)
|
April 1, 1986
Severe retinal vaso-occlusive disease in systemic lupus erythematous
D A Jabs, S L Fine, M C Hochberg, et al.
The Journal of Infectious Diseases
|
February 25, 2003
Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis
Adriana Weinberg, Douglas A Jabs, Sunwen Chou, et al.
Ophthalmology
|
August 3, 2005
Mycophenolate mofetil therapy for inflammatory eye disease
Jennifer E Thorne, Douglas A Jabs, Faqir A Qazi, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
January 26, 2010
Mitochondrial haplogroups are associated with risk of neuroretinal disorder in HIV-positive patients
Sher L Hendrickson, Douglas A Jabs, Mark Van Natta, et al.
Page
of 37
Search research articles
Search
Showing results (191-200 of 367) with videos related to
Sort By:
Page
of 37
Investigative Ophthalmology & Visual Science
|
May 1, 1987
Bullous pemphigoid autoantibodies are markers of corneal epithelial hemidesmosomes
G J Anhalt, H D Jampel, H P Patel, et al.
Ophthalmology
|
September 8, 2007
Periocular triamcinolone and photodynamic therapy for subfoveal choroidal neovascularization in age-related macular degeneration
, Marta M Gilson, Neil M Bressler, et al.
American Journal of Ophthalmology
|
October 29, 2021
Reply to Comment on: Classification Criteria for Behçet Disease Uveitis
Annabelle A Okada, Alan G Palestine, Michal Kramer, et al.
Ophthalmology
|
July 13, 2014
Author reply: To PMID 24359625
Russell W Read, Grace Levy-Clarke, Douglas A Jabs, et al.
Ophthalmology
|
December 24, 2013
Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders
Grace Levy-Clarke, Douglas A Jabs, Russell W Read, et al.
Arthritis and Rheumatism
|
July 1, 1989
Characterization of the class I HLA 9.2-kb PVU II restriction fragment length polymorphism. Linkage to HLA-A and lack of disease association
J M Ahearn, J J Calomiris, F M Wigley, et al.
Archives of Ophthalmology (Chicago, Ill. : 1960)
|
April 1, 1986
Severe retinal vaso-occlusive disease in systemic lupus erythematous
D A Jabs, S L Fine, M C Hochberg, et al.
The Journal of Infectious Diseases
|
February 25, 2003
Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis
Adriana Weinberg, Douglas A Jabs, Sunwen Chou, et al.
Ophthalmology
|
August 3, 2005
Mycophenolate mofetil therapy for inflammatory eye disease
Jennifer E Thorne, Douglas A Jabs, Faqir A Qazi, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
January 26, 2010
Mitochondrial haplogroups are associated with risk of neuroretinal disorder in HIV-positive patients
Sher L Hendrickson, Douglas A Jabs, Mark Van Natta, et al.
Page
of 37